Literature DB >> 25547995

Adenosine deaminase inhibitor EHNA exhibits a potent anticancer effect against malignant pleural mesothelioma.

Yasuhiro Nakajima1, Takeshi Kanno, Toshio Nagaya, Kozo Kuribayashi, Takashi Nakano, Akinobu Gotoh, Tomoyuki Nishizaki.   

Abstract

BACKGROUND/AIMS: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor and an effective therapy has been little provided as yet. The present study investigated the possibility for the adenosine deaminase (ADA) inhibitor EHNA as a target of MPM treatment.
METHODS: MTT assay, TUNEL staining, monitoring of intracellular adenosine concentrations, and Western blotting were carried out in cultured human MPM cell lines without and with knocking-down ADA. The in vivo effect of EHNA was assessed in mice inoculated with NCI-H2052 MPM cells.
RESULTS: EHNA induced apoptosis of human MPM cell lines in a concentration (0.01-1 mM)- and treatment time (24-48 h)-dependent manner, but such effect was not obtained with another ADA inhibitor pentostatin. EHNA increased intracellular adenosine concentrations in a treatment time (3-9 h)-dependent manner. EHNA-induced apoptosis of MPM cells was mimicked by knocking-down ADA, and the effect was neutralized by the adenosine kinase inhibitor ABT-702. EHNA clearly suppressed tumor growth in mice inoculated with NCI-H2052 MPM cells.
CONCLUSION: The results of the present study show that EHNA induces apoptosis of MPM cells by increasing intracellular adenosine concentrations, to convert to AMP, and effectively prevents MPM cell proliferation. This suggests that EHNA may be useful for treatment of the tragic neoplasm MPM.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25547995     DOI: 10.1159/000369674

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  10 in total

Review 1.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

2.  ADORA1 Promotes Hepatocellular Carcinoma Progression via PI3K/AKT Pathway.

Authors:  Sheng Ni; Qian Wei; Li Yang
Journal:  Onco Targets Ther       Date:  2020-12-01       Impact factor: 4.147

3.  Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.

Authors:  Zhao-Wei Gao; Lan Yang; Chong Liu; Xi Wang; Wen-Tao Guo; Hui-Zhong Zhang; Ke Dong
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

4.  Identification of Adenosine Deaminase Inhibitors by Metal-binding Pharmacophore Screening.

Authors:  Rebecca N Adamek; Paul Ludford; Stephanie M Duggan; Yitzhak Tor; Seth M Cohen
Journal:  ChemMedChem       Date:  2020-10-14       Impact factor: 3.466

5.  Development of Adenosine Deaminase-Specific IgY Antibodies: Diagnostic and Inhibitory Application.

Authors:  Agnieszka Łupicka-Słowik; Mateusz Psurski; Renata Grzywa; Kamila Bobrek; Patrycja Smok; Maciej Walczak; Andrzej Gaweł; Tadeusz Stefaniak; Józef Oleksyszyn; Marcin Sieńczyk
Journal:  Appl Biochem Biotechnol       Date:  2017-10-17       Impact factor: 2.926

6.  Adenosinergic Signaling Alters Natural Killer Cell Functional Responses.

Authors:  Andrea M Chambers; Jiao Wang; Kyle B Lupo; Hao Yu; Nadia M Atallah Lanman; Sandro Matosevic
Journal:  Front Immunol       Date:  2018-10-30       Impact factor: 7.561

7.  Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities.

Authors:  Jonathan D Geiger; Nabab Khan; Madhuvika Murugan; Detlev Boison
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810

8.  Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms.

Authors:  Barbara Kutryb-Zajac; Patrycja Koszalka; Paulina Mierzejewska; Alicja Bulinska; Magdalena A Zabielska; Karolina Brodzik; Aleksandra Skrzypkowska; Lukasz Zelazek; Iwona Pelikant-Malecka; Ewa M Slominska; Ryszard T Smolenski
Journal:  J Cell Mol Med       Date:  2018-10-05       Impact factor: 5.310

Review 9.  Purine-Metabolising Enzymes and Apoptosis in Cancer.

Authors:  Marcella Camici; Mercedes Garcia-Gil; Rossana Pesi; Simone Allegrini; Maria Grazia Tozzi
Journal:  Cancers (Basel)       Date:  2019-09-12       Impact factor: 6.639

Review 10.  Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer.

Authors:  Galina Zhulai; Eugenia Oleinik; Mikhail Shibaev; Kirill Ignatev
Journal:  Biomolecules       Date:  2022-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.